{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:49:19Z","timestamp":1767894559965,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00115-019-00806-x","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T13:05:09Z","timestamp":1568725509000},"page":"1254-1260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Varicella-zoster- und Herpes-zoster-Impfindikation bei Multipler Sklerose: aktuelle Situation","Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation"],"prefix":"10.1007","volume":"90","author":[{"given":"Alexander","family":"Winkelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha","family":"L\u00f6bermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe K.","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"806_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12879-019-3691-2","volume":"19","author":"M Caputo","year":"2019","unstructured":"Caputo\u00a0M, Horn\u00a0J, Karch\u00a0A et al (2019) Herpes zoster incidence in Germany\u2014an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. BMC Infect Dis 19:99","journal-title":"BMC Infect Dis"},{"key":"806_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","volume":"32","author":"BAC Cree","year":"2019","unstructured":"Cree\u00a0BAC, Mares\u00a0J, Hartung\u00a0HP (2019) Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol 32:365\u2013377","journal-title":"Curr Opin Neurol"},{"key":"806_CR3","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham\u00a0AL, Lal\u00a0H, Kovac\u00a0M et\u00a0al (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of Age or older. N\u00a0Engl J Med 375:1019\u20131032","journal-title":"N Engl J Med"},{"key":"806_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12879-018-3395-z","volume":"18","author":"D Curran","year":"2018","unstructured":"Curran\u00a0D, Schmidt-Ott\u00a0R, Schutter\u00a0U et al (2018) Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. BMC Infect Dis 18:496","journal-title":"BMC Infect Dis"},{"key":"806_CR5","first-page":"1","volume-title":"Gilenya (fingolimod), Product Information as approved by the CHMP","author":"EMA","year":"2015","unstructured":"EMA (2015) Gilenya (fingolimod), Product Information as approved by the CHMP. EMA, Amsterdam, S\u00a01\u201352"},{"key":"806_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1474-4422(17)30469-6","volume":"17","author":"M Filippi","year":"2018","unstructured":"Filippi\u00a0M, Preziosa\u00a0P, Meani\u00a0A et\u00a0al (2018) Prediction of a\u00a0multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a\u00a0retrospective study. Lancet Neurol 17:133\u2013142","journal-title":"Lancet Neurol"},{"key":"806_CR7","first-page":"95","volume":"41","author":"G Freer","year":"2018","unstructured":"Freer\u00a0G, Pistello\u00a0M (2018) Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol 41:95\u2013105","journal-title":"New Microbiol"},{"key":"806_CR8","volume-title":"Schutzimpfungs-Richtlinie: Umsetzung der STIKO-Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff","author":"GBA","year":"2019","unstructured":"GBA (2019) Schutzimpfungs-Richtlinie: Umsetzung der STIKO-Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. GBA, Berlin. \nhttps:\/\/www.g-ba.de\/beschluesse\/3702\/"},{"key":"806_CR9","volume-title":"Fachinformation Shingrix","author":"GlaxoSmithKline","year":"2018","unstructured":"GlaxoSmithKline (2018) Fachinformation Shingrix. GlaxoSmithKline, Brentford"},{"key":"806_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1386-6532(03)00005-2","volume":"26","author":"G Gross","year":"2003","unstructured":"Gross\u00a0G, Schofer\u00a0H, Wassilew\u00a0S et\u00a0al (2003) Herpes zoster guideline of the German Dermatology Society (DDG). J\u00a0Clin Virol 26:277\u2013289","journal-title":"J Clin Virol"},{"key":"806_CR11","volume-title":"Versorgungsatlas","author":"J Holstiege","year":"2017","unstructured":"Holstiege\u00a0J, Steffen\u00a0A, Goffrier\u00a0B et\u00a0al (2017) Epidemiologie der Multiplen Sklerose \u2013 eine populationsbasierte deutschlandweite Studie. In: Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland (Zi) (Hrsg) Versorgungsatlas. Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland (Zi), Berlin"},{"issue":"11","key":"806_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/v10110609","volume":"10","author":"PGE Kennedy","year":"2018","unstructured":"Kennedy\u00a0PGE, Gershon\u00a0AA (2018) Clinical features of Varicella-zoster virus infection. Viruses 10(11):609. \nhttps:\/\/doi.org\/10.3390\/v10110609","journal-title":"Viruses"},{"key":"806_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.vaccine.2018.02.029","volume":"36","author":"M Kovac","year":"2018","unstructured":"Kovac\u00a0M, Lal\u00a0H, Cunningham\u00a0AL et\u00a0al (2018) Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine 36:1537\u20131541","journal-title":"Vaccine"},{"key":"806_CR14","doi-asserted-by":"publisher","first-page":"k5095","DOI":"10.1136\/bmj.k5095","volume":"364","author":"P Le","year":"2019","unstructured":"Le\u00a0P, Rothberg\u00a0M (2019) Herpes zoster infection. BMJ 364:k5095","journal-title":"BMJ"},{"key":"806_CR15","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1007\/s00115-018-0492-6","volume":"89","author":"M Lobermann","year":"2018","unstructured":"Lobermann\u00a0M, Handorn\u00a0B, Winkelmann\u00a0A et\u00a0al (2018) Multiple sclerosis and hepatitis B vaccination: what does the verdict of the European Court of Justice on liability after vaccination mean? Nervenarzt 89:1172\u20131178","journal-title":"Nervenarzt"},{"key":"806_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00115-009-2865-3","volume":"81","author":"M Lobermann","year":"2010","unstructured":"Lobermann\u00a0M, Winkelmann\u00a0A, Reisinger\u00a0EC et\u00a0al (2010) Vaccination and multiple sclerosis. Nervenarzt 81:181\u2013193","journal-title":"Nervenarzt"},{"issue":"Suppl 1","key":"806_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000367614","volume":"72","author":"FD Lublin","year":"2014","unstructured":"Lublin\u00a0FD (2014) New multiple sclerosis phenotypic classification. Eur Neurol 72(Suppl 1):1\u20135","journal-title":"Eur Neurol"},{"key":"806_CR18","volume-title":"Prescribing information Mayzent","author":"Novartis","year":"2019","unstructured":"Novartis (2019) Prescribing information Mayzent. Novartis, Basel"},{"key":"806_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich\u00a0DS, Lucchinetti\u00a0CF, Calabresi\u00a0PA (2018) Multiple sclerosis. N\u00a0Engl J Med 378:169\u2013180","journal-title":"N Engl J Med"},{"key":"806_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14656566.2018.1446944","volume":"19","author":"PS Rommer","year":"2018","unstructured":"Rommer\u00a0PS, Zettl\u00a0UK (2018) Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother 19:483\u2013498","journal-title":"Expert Opin Pharmacother"},{"key":"806_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00103-019-02882-5","volume":"62","author":"A Siedler","year":"2019","unstructured":"Siedler\u00a0A, Koch\u00a0J, Garbe\u00a0E et\u00a0al (2019) Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch\u00a0Institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62:352\u2013376","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"806_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12879-018-3137-2","volume":"18","author":"T Skripuletz","year":"2018","unstructured":"Skripuletz\u00a0T, Pars\u00a0K, Schulte\u00a0A et\u00a0al (2018) Varicella zoster virus infections in neurological patients: a\u00a0clinical study. BMC Infect Dis 18:238","journal-title":"BMC Infect Dis"},{"issue":"50","key":"806_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.17886\/EpiBull-2017-059.2","volume":"23","author":"St\u00e4ndige Impfkommission (Stiko)","year":"2018","unstructured":"St\u00e4ndige Impfkommission (Stiko) (2018) Wissenschaftliche Begr\u00fcndung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epidemiol Bull 23(50):541\u2013567. \nhttps:\/\/doi.org\/10.17886\/EpiBull-2017-059.2","journal-title":"Epidemiol Bull"},{"key":"806_CR24","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson\u00a0AJ, Baranzini\u00a0SE, Geurts\u00a0J et\u00a0al (2018) Multiple sclerosis. Lancet 391:1622\u20131636","journal-title":"Lancet"},{"key":"806_CR25","doi-asserted-by":"publisher","first-page":"k4029","DOI":"10.1136\/bmj.k4029","volume":"363","author":"AC Tricco","year":"2018","unstructured":"Tricco\u00a0AC, Zarin\u00a0W, Cardoso\u00a0R et al (2018) Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ 363:k4029","journal-title":"BMJ"},{"key":"806_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","volume":"62","author":"N Wagner","year":"2019","unstructured":"Wagner\u00a0N, Assmus\u00a0F, Arendt\u00a0G et al (2019) Impfen bei Immundefizienz: Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62:494\u2013515","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"806_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00115-011-3360-1","volume":"83","author":"A Winkelmann","year":"2012","unstructured":"Winkelmann\u00a0A, Loebermann\u00a0M, Reisinger\u00a0EC et\u00a0al (2012) Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations. Nervenarzt 83:236\u2013242","journal-title":"Nervenarzt"},{"key":"806_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","volume":"12","author":"A Winkelmann","year":"2016","unstructured":"Winkelmann\u00a0A, Loebermann\u00a0M, Reisinger\u00a0EC et al (2016) Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 12:217\u2013233","journal-title":"Nat Rev Neurol"},{"key":"806_CR29","volume-title":"Diagnostik und Therapie neurologischer Erkrankungen","author":"UK Zettl","year":"2019","unstructured":"Zettl\u00a0UK, Sieb\u00a0JP (2019) Diagnostik und Therapie neurologischer Erkrankungen. Urban & Fischer, M\u00fcnchen, Jena"},{"key":"806_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.autrev.2011.05.008","volume":"11","author":"UK Zettl","year":"2012","unstructured":"Zettl\u00a0UK, Stuve\u00a0O, Patejdl\u00a0R (2012) Immune-mediated CNS diseases: a\u00a0review on nosological classification and clinical features. Autoimmunity Reviews 11:167\u2013173","journal-title":"Autoimmunity Reviews"},{"key":"806_CR31","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1080\/21645515.2018.1446718","volume":"14","author":"B Zoch-Lesniak","year":"2018","unstructured":"Zoch-Lesniak\u00a0B, Tolksdorf\u00a0K, Siedler\u00a0A (2018) Trends in herpes zoster epidemiology in Germany based on primary care sentinel surveillance data, 2005\u20132016. Hum Vaccines Immunother 14:1807\u20131814","journal-title":"Hum Vaccines Immunother"},{"key":"806_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40520-018-0956-3","volume":"30","author":"E Zorzoli","year":"2018","unstructured":"Zorzoli\u00a0E, Pica\u00a0F, Masetti\u00a0G et\u00a0al (2018) Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies. Aging Clin Exp Res 30:693\u2013702","journal-title":"Aging Clin Exp Res"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-00806-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T23:32:23Z","timestamp":1600212743000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-00806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-00806-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"17 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Winkelmann erhielt Vortragshonorare und\/oder Reisekostenzusch\u00fcsse f\u00fcr den Besuch wissenschaftlicher Konferenzen folgender Firmen: Bayer Health Care, Celgene, Merck Serono, Novartis, Sanofi-Genzyme und TEVA. M.\u00a0L\u00f6bermann hat klinische Studien mit folgenden Sponsoren durchgef\u00fchrt: Astellas Pharma, GlaxoSmithKline, Novartis Vaccines, Roche Pharma, Sanofi Pasteur MSD, Sequirus und Valneva. Er hat Vortragshonorare von Gilead, Sanofi und Janssen erhalten. U.K.\u00a0Zettl erhielt Vortragshonorare und\/oder Reisekostenzusch\u00fcsse f\u00fcr den Besuch wissenschaftlicher Konferenzen folgender Firmen: Almirall, Alexion, Bayer, Biogen, Celgene, Merck Serono, Novartis, Octapharma, Roche, Sanofi-Genzyme und TEVA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}